The Coronavirus vaccine developed by CanSino Biologics, a Chinese biotechnology company, is 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection, results of a multination phase-III clinical trial have shown.
According to SAPM on Health, Dr. Faisal Sultan, in the Pakistani subset, the Cansino vaccine offered 75% protection against symptomatic cases and 100% protection against severe infection.
Pakistan Ranks Next to Afghanistan on Stunting Growth Index
Dr. Faisal added that no serious safety concerns and side-effects of the Cansino vaccine were reported during the multination clinical trial.
Clinical trial data (phase-3) of a one-dose Ad5-nCoV vaccine for Covid (Cansino Bio) received. Interim analysis by the Independent Data Monitoring Committee shows 65.7% efficacy at preventing symptomatic cases and 90.98% at preventing severe disease (multicountry analysis).
— Faisal Sultan (@fslsltn) February 8, 2021
Pakistan has already booked enough CanSino’s COVID-19 vaccine doses to vaccinate 20 million citizens.
Japan Develops Machine that Delivers COVID-19 Results in 80 Minutes
CanSino’s vaccine is the third Chinese vaccine to hit the markets. Sinovac and Sinopharm have developed the other two and both have been approved for use in numerous countries.
Pakistan has received 0.5 million doses of Sinopharm’s Coronavirus vaccine while another 0.5 million doses of the vaccine will reach the country soon. 1 million doses of Sinopharm will help the government vaccinate 0.5 million citizens.
GIPHY App Key not set. Please check settings